Image Source: unsplash

Mpox Outbreak Global Health Emergency

The urgency to address the Mpox outbreak in Africa has become paramount, with more than 14,000 reported cases and 524 deaths. This viral illness, caused by the monkeypox virus, primarily spreads through close contact with infected individuals, including via sexual contact. The impact of Mpox on public health in the region is significant, especially considering the emergence of a new form with a higher death rate estimated at 3-4%.

Global concern over the spread of Mpox in Africa is escalating as statistics reveal a rapid increase in cases and deaths compared to previous years. The World Health Organization (WHO) has declared Mpox outbreaks in Africa as a global health emergency, emphasizing the need for immediate action to mitigate its effects. The identification of high-risk countries with Mpox infections underscores the continental security concerns posed by this infectious disease.

Experts like Salim Abdool Karim, a South African infectious diseases expert and Chair of Africa CDC emergency group, have highlighted the severity of the situation. Collaborative efforts are crucial to control the spread of Mpox and prevent further fatalities. The necessity for global support and resources to combat this crisis cannot be overstated.

Mpox Virus and Its Transmission

Overview of Mpox Virus

Mpox, a viral illness caused by the monkeypox virus, poses a significant threat to public health in Africa. The transmission modes of Mpox primarily involve physical contact with infected individuals, materials, or animals. This close contact facilitates the spread of the virus, making it crucial to understand how easily Mpox can be transmitted within communities.

EUL Procedure and Mpox Vaccines

The Emergency Use Authorization (EUL) plays a vital role in expediting the availability of vaccines during public health emergencies like the Mpox outbreak in Africa. By streamlining the process for vaccine approval, the EUL procedure enables swift procurement and distribution of vaccines by key partners such as Gavi and UNICEF. Submitting comprehensive data on vaccine safety, effectiveness, and quality is essential in ensuring that only reliable vaccines receive authorization for emergency use.

WHO-recommended vaccines for Mpox play a crucial role in combating the virus and curbing its spread across regions affected by outbreaks. These vaccines are pivotal in protecting vulnerable populations from contracting Mpox and reducing the overall burden on healthcare systems struggling to manage the influx of cases.

Global Health Emergency Declaration

The World Health Organization (WHO) has officially declared the Mpox outbreaks in Africa as a global health emergency, signaling the urgent need for international attention and coordinated response efforts. The statistics on confirmed cases and deaths reported in multiple African countries paint a concerning picture of the escalating crisis. Particularly alarming is the situation in the Democratic Republic of the Congo, where more than 14,000 cases and 511 deaths have been recorded since the beginning of 2024.

Rapid Spread and Increased Mortality

The Mpox outbreak has taken a dire turn with the emergence of a new form of the virus exhibiting a higher death rate. This development has led to a significant increase in both cases and fatalities compared to previous years, raising fears of Mpox crossing national borders and potentially sparking a global outbreak. The severity of this situation cannot be understated, as healthcare systems grapple with the overwhelming burden imposed by Mpox infections.

Continental Security Concerns

High-risk countries in Africa grappling with Mpox infections face critical challenges in containing the spread of the virus. The public health emergency status of the Mpox outbreak in Africa underscores the need for swift and decisive action to mitigate its impact on vulnerable populations. The introduction of the new clade Ib of the Mpox virus has heightened concerns about its ability to spread efficiently from person to person, further complicating containment efforts.

Expert opinions from Dr. Jean Kaseya, Head of Africa CDC, emphasize the gravity of the situation, highlighting the urgent need for collaborative measures to address this growing threat. The current scenario demands immediate intervention at both regional and global levels to prevent further escalation and protect communities from the devastating consequences of Mpox outbreaks.

Addressing the Urgency of Mpox Outbreak Mitigation

The current Mpox outbreak in Africa demands immediate action to mitigate its devastating impact on public health. Collaborative efforts are essential to control the spread of Mpox and prevent further fatalities, especially in high-risk regions where the virus is rapidly circulating. The necessity of global support and resources cannot be overstated in combating the Mpox crisis effectively. By pooling together expertise, resources, and coordinated strategies, stakeholders can work towards containing the outbreak and safeguarding vulnerable populations from the severe consequences of Mpox infections. It is imperative that governments, international organizations, healthcare professionals, and communities unite in a concerted effort to address this pressing public health emergency and prevent the escalation of the Mpox outbreak in Africa.

1. What is the Mpox virus?

• The Mpox virus, previously known as Monkeypox, is a viral zoonosis, meaning it’s a virus transmitted to humans from animals. It is similar to the virus that causes smallpox, but generally less severe.

2. What causes the Mpox virus?

• The Mpox virus is caused by the Mpox virus, a member of the Orthopoxvirus genus. It is typically transmitted to humans through close contact with an infected animal or person, including contact with bodily fluids, skin lesions, or respiratory droplets.

3. What are the symptoms of Mpox?

• Symptoms of Mpox include:
  • Fever
  • Headache
  • Muscle aches
  • Backache
  • Swollen lymph nodes
  • Chills
  • Exhaustion
  • A rash that starts on the face and then spreads to other parts of the body, evolving from macules to pustules and crusts.

4. How is the Mpox virus transmitted?

• The Mpox virus can be transmitted through direct contact with the blood, bodily fluids, or skin/mucosal lesions of infected animals or humans. Human-to-human transmission occurs primarily through respiratory droplets during prolonged face-to-face contact, direct contact with body fluids, or contaminated objects like bedding or clothing.

5. Is there a vaccine for the Mpox virus?

• Yes, vaccines used to eradicate smallpox also provide protection against the Mpox virus. A newer vaccine, known as the JYNNEOS (Imvamune or Imvanex), has been approved for preventing Mpox. Vaccination is recommended for people who are at risk, including healthcare workers and those exposed to the virus.

6. Who is at risk of contracting Mpox?

• People living in or near forested areas where infected animals are found, healthcare workers, and individuals in close contact with infected persons or animals are at higher risk.

7. How can Mpox be prevented?

• Preventive measures include:
  • Avoiding contact with animals that could harbor the virus, especially sick or dead animals.
  • Practicing good hygiene, such as washing hands with soap and water.
  • Avoiding close contact with infected individuals.
  • Using personal protective equipment (PPE) when caring for infected patients.
  • Vaccination for those at high risk.

8. What should I do if I suspect I have been exposed to the Mpox virus?

• If you suspect exposure, seek medical attention immediately. Early diagnosis and supportive care can help manage the symptoms. Inform healthcare providers about your recent travel history and any potential exposure to infected animals or individuals.

9. Is Mpox fatal?

• Mpox is generally less severe than smallpox. However, it can be fatal in some cases, particularly in young children, pregnant women, and individuals with compromised immune systems. The case fatality rate varies but is usually lower than 10%.

10. Where is Mpox most commonly found?

• Mpox is primarily found in Central and West African countries. However, cases have been reported in other regions due to international travel or the global movement of animals.